Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
22 March 2024Website:
http://www.lenz-tx.comNext earnings report:
29 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 5 min agoDividend
Analysts recommendations
Institutional Ownership
LENZ Latest News
On Sunday, Corxel Pharmaceuticals and LENZ Therapeutics LENZ released topline data from the Phase 3 JX07001 trial of LNZ100 in patients with presbyopia in China.
Primary endpoint was met with 74% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours post treatment，and maintaining their optimal distance visual acuity (i.e., not losing 5 or more letters). The difference in efficacy was statistically significant in the LNZ100 treatment group compared to the vehicle group (p
FDA sets Prescription Drug User Fee Act (PDUFA) target date of August 8, 2025 FDA sets Prescription Drug User Fee Act (PDUFA) target date of August 8, 2025
SAN DIEGO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first and only aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, today announced that company management will participate in the following upcoming investor conferences:
LENZ Therapeutics (NASDAQ: LENZ ) just reported results for the first quarter of 2024. LENZ Therapeutics reported earnings per share of -$3.53.
LENZ Therapeutics, Inc. (NASDAQ:LENZ ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Dan Chevallard - CFO Eef Schimmelpennink - President & CEO Shawn Olsson - Chief Commercial Officer Marc Odrich - Chief Medical Officer Conference Call Participants Pavan Patel - Bank of America Yigal Nochomovitz - Citigroup Joseph Catanzaro - Piper Sandler Marc Goodman - Leerink Lachlan Hanbury-Brown - William Blair Matthew Caufield - H. C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the LENZ Therapeutics Second Quarter 2024 Conference Call.
SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, August 14, 2024 at 4:30 p.m. ET to report its second quarter 2024 financial results and provide a business update.
Lenz Therapeutics said on Wednesday its experimental drugs to treat loss of near vision met the main goal of a late-stage study, sending its shares up nearly 23% before the bell.
What type of business is LENZ Therapeutics?
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
What sector is LENZ Therapeutics in?
LENZ Therapeutics is in the Healthcare sector
What industry is LENZ Therapeutics in?
LENZ Therapeutics is in the Biotechnology industry
What country is LENZ Therapeutics from?
LENZ Therapeutics is headquartered in United States
When did LENZ Therapeutics go public?
LENZ Therapeutics initial public offering (IPO) was on 22 March 2024
What is LENZ Therapeutics website?
https://www.lenz-tx.com
Is LENZ Therapeutics in the S&P 500?
No, LENZ Therapeutics is not included in the S&P 500 index
Is LENZ Therapeutics in the NASDAQ 100?
No, LENZ Therapeutics is not included in the NASDAQ 100 index
Is LENZ Therapeutics in the Dow Jones?
No, LENZ Therapeutics is not included in the Dow Jones index
When was LENZ Therapeutics the previous earnings report?
No data
When does LENZ Therapeutics earnings report?
The next expected earnings date for LENZ Therapeutics is 29 November 2024